Clinical Trials Logo

Clinical Trial Summary

This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are at a higher risk for failure of CAR-T therapy.


Clinical Trial Description

E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. This trial is designed to augment lymphodepletion prior to CAR-T cells by administration of a targeted immunotoxin against CD25-expressing T-cells. CD25 is expressed at high levels on Tregs but also on activated effector T cells. The use of the CAR-T cell product and associated apheresis and LD chemotherapy is considered standard of care (SOC). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04855253
Study type Interventional
Source Masonic Cancer Center, University of Minnesota
Contact Cancer Center Clinical Trials Office
Phone 612-676-4200
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date May 1, 2021
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT03287817 - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma Phase 1/Phase 2
Recruiting NCT03990961 - Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) Phase 2
Recruiting NCT04555811 - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Phase 1
Recruiting NCT04189952 - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma Phase 2
Not yet recruiting NCT04572763 - Copanlisib Plus Venetoclax in R/R DLBCL Phase 1/Phase 2
Not yet recruiting NCT03873025 - A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Phase 1/Phase 2
Recruiting NCT01949818 - Treatment of Diffuse Large B Cell Lymphoma Phase 4
Completed NCT01459887 - Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma Phase 3
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Tumors Phase 1/Phase 2
Recruiting NCT04316624 - A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy Phase 1
Not yet recruiting NCT04052061 - QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Phase 1
Recruiting NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1/Phase 2
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Not yet recruiting NCT04726787 - RadiothErapy priMIng for CAR-T N/A
Recruiting NCT04622579 - Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years Phase 2
Active, not recruiting NCT02951728 - Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT01679119 - Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy Phase 2
Recruiting NCT01277172 - TREatment of degeNerative and Neoplastic Diseases With Rituximab Phase 2/Phase 3